Remarkably, pathogenic variants in BRCA1/2 were present in patients both with and without clinical benefit, whereas variants in other known homologous recombination repair (HRR) genes were identified exclusively in tumor samples from patients with clinical benefit (ABRAXAS1, FANCA, and RAD51C). Here, ABRAXAS1 is linked to neoplasm.